EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Serum IL-33 Concentrations and the IL-12/IFN-? Axis According to Therapeutic Strategy in Rheumatoid Arthritis

Jasmina Jocic, Radiša Pavlovic, Ivan Jovanovic, Bojana Stamenkovic, Nikola Jocic, Sanja Stojanovic, Aleksandra Tomic Lucic, Sladana Pavlovic

Medical Principles and Practice · 2026-11-09

DOI: 10.1159/mpp/adpag041 ↗
AbstractBibliografische Angaben

Abstract

Abstract Introduction: Interleukin-33 (IL-33) is involved in inflammatory pathways relevant to rheumatoid arthritis (RA) and may interact with the IL-12/interferon-gamma (IFN-γ) axis. However, the relationship between circulating IL-33 concentrations and different therapeutic strategies remains incompletely understood. Subjects and Methods: In this prospective observational study with cross-sectional analysis, 189 consecutive RA patients were stratified according to treatment: methotrexate (MTX), MTX plus TNF inhibitors (MTX+TNFi), tocilizumab (TCZ), and DMARD-naïve patients. Serum IL-33 concentrations were measured by ELISA. Disease activity indices (DAS28-ESR, CDAI, SDAI), inflammatory markers, and serum IL-12 and IFN-γ levels were assessed. Results: IL-33 concentrations differed across therapeutic groups, with the highest levels observed in DMARD-naïve patients and lower levels in those receiving biologic therapy, particularly TCZ. IL-33 was associated with disease activity parameters and showed a modest positive correlation with IL-12. IFN-γ concentrations also differed among treatment groups, with the lowest levels observed in TCZ-treated patients. Conclusions: Serum IL-33 concentrations varied across therapeutic groups in rheumatoid arthritis and were associated with selected indicators of inflammatory activity. Further studies are needed to clarify the role of IL-33 in the immunopathology of rheumatoid arthritis.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →